Canagliflozin

SGLT2 Inhibitor — Diabetes

• Drug Class: SGLT2 Inhibitor
• Category: Diabetes
• Type: Small Molecule
• SMILES: Cc1ccc(cc1-c1ccc(cc1F)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)-c1ccc(F)cc1-c1ccc2c(c1)OCO2

What is Canagliflozin?

Canagliflozin is a groundbreaking medication belonging to the class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. Primarily utilized in the management of type 2 diabetes mellitus, it offers a novel approach to glycemic control by targeting glucose reabsorption in the kidneys. Available under the brand name Invokana, as well as in generic forms, canagliflozin has become a significant therapeutic option for millions of patients seeking to improve their blood sugar levels and reduce associated cardiovascular and renal complications. Its introduction marked a pivotal shift in diabetes treatment, moving beyond insulin-sensitizing or secretagogue mechanisms to a pathway directly influenced by renal physiology.

Generic vs. Brand Names

Canagliflozin is widely recognized by its most common brand name, Invokana, manufactured by Janssen Pharmaceuticals. However, as patents expire, generic versions of canagliflozin have become available, offering a more cost-effective alternative for patients and healthcare systems. Regardless of the name, the active pharmaceutical ingredient remains the same, providing the same therapeutic benefits and requiring the same careful consideration of dosage, administration, and potential side effects.

Mechanism of Action

The therapeutic efficacy of canagliflozin stems from its selective inhibition of the sodium-glucose cotransporter 2 (SGLT2) protein. This protein is predominantly located in the proximal tubules of the kidneys, where it plays a critical role in reabsorbing approximately 90% of the filtered glucose back into the bloodstream. In individuals with type 2 diabetes, this reabsorptive process can be upregulated, contributing to hyperglycemia.

Targeting Renal Glucose Reabsorption

Canagliflozin works by competitively binding to the SGLT2 transporter. This binding prevents the SGLT2 protein from facilitating the reabsorption of glucose from the glomerular filtrate back into the systemic circulation. As a result, a significant portion of the filtered glucose is instead excreted in the urine, a process known as glycosuria. This reduction in renal glucose reabsorption leads to a decrease in plasma glucose concentrations, both fasting and postprandial.

Beyond Glycemic Control

The benefits of SGLT2 inhibitors like canagliflozin extend beyond simple glucose lowering. By increasing urinary glucose excretion, they reduce the overall glucose load in the body. Furthermore, studies have indicated that SGLT2 inhibition may have beneficial effects on cardiovascular and renal outcomes, independent of glycemic control. These effects are thought to be mediated through various mechanisms, including osmotic diuresis, natriuresis, reduction in intraglomerular pressure, and improved cardiac energetics.

Clinical Uses & Indications

Canagliflozin is approved by regulatory bodies, including the U.S. Food and Drug Administration (FDA), for several key indications in the management of type 2 diabetes mellitus. Its utility is primarily focused on improving glycemic control, but its expanded indications highlight its multifaceted benefits.

FDA-Approved Uses

• To improve glycemic control in adults with type 2 diabetes mellitus: Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, thiazolidinediones, and insulin.
• To reduce the risk of major cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD): This is a significant indication, demonstrating the drug's cardioprotective properties. It has been shown to reduce the risk of major adverse cardiovascular events (MACE), such as heart attack, stroke, and cardiovascular death.
• To reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, and cardiovascular death in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria: This indication underscores the nephroprotective effects of canagliflozin, making it a valuable option for patients with diabetic kidney disease.

Off-Label Considerations

While the primary indications are well-established, ongoing research continues to explore potential off-label uses for canagliflozin and other SGLT2 inhibitors, particularly in conditions involving metabolic dysfunction or cardiovascular and renal compromise.

Dosage & Administration

Canagliflozin is administered orally and is available in different strengths to cater to individual patient needs and treatment regimens. The dosage and frequency are determined by the treating physician based on factors such as glycemic control, renal function, and the presence of concomitant cardiovascular or renal disease.

Common Dosage Forms and Strengths

Canagliflozin is typically available as:

• Tablets containing 100 mg or 300 mg of canagliflozin.

Administration Guidelines

• Usual Starting Dose: The recommended starting dose for most patients is 100 mg once daily.
• Maximum Dose: The maximum recommended dose is 300 mg once daily.
• Timing: The tablet can be taken once daily, either in the morning or in the evening, with or without food.
• Renal Impairment: Dosage adjustments may be necessary in patients with moderate to severe renal impairment. The 300 mg dose is generally not recommended for patients with an eGFR below 45 mL/min/1.73 m².
• Concomitant Medications: When used in combination with other medications, particularly those that can lower blood glucose, adjustments to the dosage of those agents may be required to mitigate the risk of hypoglycemia.

Side Effects & Safety

Like all medications, canagliflozin can cause side effects. While many patients tolerate it well, it is crucial to be aware of potential adverse events, ranging from common and mild to rare but serious.

Common Side Effects

The most frequently reported side effects of canagliflozin include:

• Genital Mycotic Infections (Yeast Infections): Both men and women can experience increased incidence of fungal infections in the genital area.
• Urinary Tract Infections (UTIs): While less common than genital infections, UTIs can occur.
• Increased urination (Polyuria): This is a direct consequence of increased glucose excretion in the urine.
• Thirst: Often associated with increased urination.
• Constipation
• Nausea
• Pain in extremity

Serious Side Effects and Warnings

While rare, some serious side effects require immediate medical attention:

• Diabetic Ketoacidosis (DKA): Canagliflozin can increase the risk of DKA, even in patients with normal or only slightly elevated blood glucose levels. Symptoms include difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness.
• Hypovolemia/Dehydration: Due to the osmotic diuretic effect, patients may experience dehydration, especially in those with impaired renal function, the elderly, or those on diuretics. Symptoms include dizziness, lightheadedness, and fainting.
• Serious Genital Infections: Although rare, severe infections, including Fournier's gangrene (necrotizing fasciitis of the perineum), have been reported.
• Amputations: An increased risk of lower limb amputations, particularly of the toe, has been observed in clinical trials. Patients with a history of peripheral vascular disease or neuropathy are at higher risk.
• Hypersensitivity Reactions: Allergic reactions, including angioedema and anaphylaxis, can occur.
• Bone Fractures: Some studies have suggested a potential increased risk of bone fractures.
• Hypoglycemia: The risk of hypoglycemia is increased when canagliflozin is used in combination with insulin or sulfonylureas.

Contraindications

Canagliflozin is contraindicated in patients with:

• Known hypersensitivity to canagliflozin or any of its excipients.
• End-stage renal disease (ESRD) or are on dialysis.

Drug Interactions

Canagliflozin can interact with other medications, potentially altering its efficacy or increasing the risk of adverse events. It is essential for healthcare providers to review a patient's complete medication list before initiating canagliflozin therapy.

Notable Interactions

• Rifampin: Concurrent use may decrease plasma concentrations of canagliflozin, potentially reducing its efficacy. Dose adjustment of canagliflozin may be needed.
• Other Antidiabetic Agents (e.g., Insulin, Sulfonylureas): Co-administration increases the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
• Diuretics: Canagliflozin can add to the diuretic and osmotic diuresis effects of diuretics, potentially increasing the risk of dehydration and hypotension. Close monitoring of volume status and blood pressure is recommended.
• CYP2C9 Inhibitors/Inducers: While canagliflozin is primarily metabolized by UGT enzymes, interactions with CYP2C9 inhibitors or inducers could potentially affect its pharmacokinetics.
• Digoxin: Canagliflozin may increase digoxin levels, requiring careful monitoring.

Molecular Properties

Understanding the molecular characteristics of canagliflozin provides insight into its physical and chemical behavior, which influences its absorption, distribution, metabolism, and excretion (ADME) properties, as well as its drug interactions and formulation.

Key Molecular Data

• Molecular Formula: C₂₄H₂₅F₂O₅
• Molecular Weight: Approximately 442.45 g/mol
• Structure Description: Canagliflozin is a synthetic C-glycoside derivative. It features a glucopyranose ring attached via a methylene bridge to a substituted biphenyl moiety. The biphenyl system is further functionalized with fluorine atoms and a benzodioxane ring. The specific stereochemistry of the chiral centers on the glucopyranose ring is crucial for its biological activity. The SMILES notation for canagliflozin is Cc1ccc(cc1-c1ccc(cc1F)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)-c1ccc(F)cc1-c1ccc2c(c1)OCO2. This notation precisely describes the connectivity and spatial arrangement of atoms within the molecule.
• Solubility: Canagliflozin is practically insoluble in water but soluble in certain organic solvents.

SMILES Notation Explained

The SMILES (Simplified Molecular Input Line Entry System) string Cc1ccc(cc1-c1ccc(cc1F)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)-c1ccc(F)cc1-c1ccc2c(c1)OCO2 provides a linear representation of the molecule's structure. It encodes information about atom types, bond orders, and branching. For instance, 'C' represents carbon, 'c' an aromatic carbon, 'F' fluorine, 'O' oxygen, and '@' indicates a chiral center with specific stereochemistry. The numbers and symbols denote ring closures and connectivity, allowing computational tools to reconstruct the 3D structure and predict molecular properties.

Analyze Canagliflozin with MolForge

Understanding the intricate molecular details of drugs like canagliflozin is paramount for drug discovery and development. MolForge's AI-powered platform offers advanced tools to explore molecular properties, predict interactions, and accelerate research.

Leveraging state-of-the-art algorithms, MolForge can analyze canagliflozin's structure, predict its binding affinities to various targets, assess its ADME properties, and identify potential off-target effects. By inputting the SMILES notation or exploring our extensive molecular database, researchers can gain deeper insights into canagliflozin's mechanism of action, potential for new therapeutic applications, and strategies for optimizing its efficacy and safety profile. Discover the power of AI in molecular discovery. Explore canagliflozin and countless other molecules by visiting our MolForge Dashboard today.